[Ip-health] New Tufts study on R&D costs

Dimasi, Joseph A. Joseph.Dimasi at tufts.edu
Sat Nov 15 02:15:36 PST 2014

Hi Jamie,

I assume that I can't enter to win the Tufts R&D Cost Estimate Prize Fund, but it's an interesting and amusing crowdsourcing type of experiment.  You might tally the results at the end and show the distribution of predictions.


Joseph A. DiMasi, Ph.D.
Director of Economic Analysis
Tufts Center for the Study of Drug Development Tufts University
75 Kneeland Street, Suite 1100
Boston, MA 02111
tel: 617-636-2116; fax: 617-636-2425
URL: http://csdd.tufts.edu

From: Ip-health [ip-health-bounces at lists.keionline.org] on behalf of Jamie Love [james.love at keionline.org]
Sent: Friday, November 14, 2014 4:14 PM
To: Outterson, Kevin
Cc: ip-health at lists.keionline.org listserve
Subject: Re: [Ip-health] New Tufts study on R&D costs

It will be interesting to see what "cost of capital" figures Tufts uses
this year.

Recently Gilead priced a series of bonds, $500 million at $2.35
percent maturing February 2020, $1,750M at 3.5 percent maturing February
2025 and $1,750M at 4.5 percent maturing February 2045.
Ip-health mailing list
Ip-health at lists.keionline.org

More information about the Ip-health mailing list